1004 related articles for article (PubMed ID: 31611651)
1. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.
Nakamura K; Smyth MJ
Cell Mol Immunol; 2020 Jan; 17(1):1-12. PubMed ID: 31611651
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Carnevalli LS; Ghadially H; Barry ST
Front Immunol; 2021; 12():633685. PubMed ID: 33953710
[TBL] [Abstract][Full Text] [Related]
3. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Hou A; Hou K; Huang Q; Lei Y; Chen W
Front Immunol; 2020; 11():783. PubMed ID: 32508809
[TBL] [Abstract][Full Text] [Related]
4. Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.
Szebeni GJ; Vizler C; Nagy LI; Kitajka K; Puskas LG
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886105
[TBL] [Abstract][Full Text] [Related]
5. Myeloid suppressor cells in cancer and autoimmunity.
Sica A; Massarotti M
J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794
[TBL] [Abstract][Full Text] [Related]
6. Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy.
Li X; Zhong J; Deng X; Guo X; Lu Y; Lin J; Huang X; Wang C
Front Immunol; 2021; 12():754196. PubMed ID: 35003065
[TBL] [Abstract][Full Text] [Related]
7. Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.
Fujimura T; Aiba S
Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32707850
[TBL] [Abstract][Full Text] [Related]
8. Targeting myeloid-derived suppressor cells for cancer immunotherapy.
Liu Y; Wei G; Cheng WA; Dong Z; Sun H; Lee VY; Cha SC; Smith DL; Kwak LW; Qin H
Cancer Immunol Immunother; 2018 Aug; 67(8):1181-1195. PubMed ID: 29855694
[TBL] [Abstract][Full Text] [Related]
9. The immunobiology of myeloid-derived suppressor cells in cancer.
Motallebnezhad M; Jadidi-Niaragh F; Qamsari ES; Bagheri S; Gharibi T; Yousefi M
Tumour Biol; 2016 Feb; 37(2):1387-406. PubMed ID: 26611648
[TBL] [Abstract][Full Text] [Related]
10. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
Front Immunol; 2018; 9():2250. PubMed ID: 30349530
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Parker KH; Beury DW; Ostrand-Rosenberg S
Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
[TBL] [Abstract][Full Text] [Related]
12. Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation.
Yang Y; Li C; Liu T; Dai X; Bazhin AV
Front Immunol; 2020; 11():1371. PubMed ID: 32793192
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
15. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.
Davis RJ; Van Waes C; Allen CT
Oral Oncol; 2016 Jul; 58():59-70. PubMed ID: 27215705
[TBL] [Abstract][Full Text] [Related]
16. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP; Zhu AX; Wang Y
Front Immunol; 2020; 11():598877. PubMed ID: 33250900
[TBL] [Abstract][Full Text] [Related]
17. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells.
Oh MH; Sun IH; Zhao L; Leone RD; Sun IM; Xu W; Collins SL; Tam AJ; Blosser RL; Patel CH; Englert JM; Arwood ML; Wen J; Chan-Li Y; Tenora L; Majer P; Rais R; Slusher BS; Horton MR; Powell JD
J Clin Invest; 2020 Jul; 130(7):3865-3884. PubMed ID: 32324593
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.
Krishnamoorthy M; Gerhardt L; Maleki Vareki S
Cells; 2021 May; 10(5):. PubMed ID: 34065010
[TBL] [Abstract][Full Text] [Related]
19. Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles.
Arkhypov I; Lasser S; Petrova V; Weber R; Groth C; Utikal J; Altevogt P; Umansky V
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878277
[TBL] [Abstract][Full Text] [Related]
20. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.
Soong RS; Anchoori RK; Yang B; Yang A; Tseng SH; He L; Tsai YC; Roden RB; Hung CF
Oncotarget; 2016 Oct; 7(42):68489-68502. PubMed ID: 27655678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
